Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Novel therapies for pancreatic cancer
Autore:
Wolff, RA;
Indirizzi:
Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA Univ Texas Houston TX USA 77030 testinal Med Oncol, Houston, TX 77030 USA
Titolo Testata:
CANCER JOURNAL
fascicolo: 4, volume: 7, anno: 2001,
pagine: 349 - 358
SICI:
1528-9117(200107/08)7:4<349:NTFPC>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
EPIDERMAL GROWTH-FACTOR; PHASE-II TRIAL; FACTOR RECEPTOR; MATRIX METALLOPROTEINASES; MITOMYCIN-C; K-RAS; MONOCLONAL-ANTIBODY; RANDOMIZED TRIAL; CLINICAL-TRIALS; GENE-THERAPY;
Keywords:
pancreatic cancer; gemcitabine; ras; farnesyl transferase inhibitors; anti-angiogenic agents; p53; matrix metalloproteinases; epidermal growth factor receptor; HER2; molecular targets;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
98
Recensione:
Indirizzi per estratti:
Indirizzo: Wolff, RA Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd,Box 426, Houston, TX 77030 USA Univ Texas 1515 Holcombe Blvd,Box 426 Houston TX USA 77030 0 USA
Citazione:
R.A. Wolff, "Novel therapies for pancreatic cancer", CANCER J, 7(4), 2001, pp. 349-358

Abstract

To date, pancreatic cancer has proved to be one of the most resistant malignancies, characterized by early local invasion and distant spread. Therefore, resection with curative intent is limited to a very small proportion ofpatients. Even in this select group, long-term survival remains very poor. Although radiotherapy and chemotherapy may provide some palliative benefits, these interventions have had minimal impact on overall survival. Over the past several years, 2'-difluoro-2'-deoxycytidine (gemcitabine) has demonstrated modest activity in advanced disease, and investigations are proceeding to expand its role in the adjuvant setting, in combination with radiotherapy, and in combination with other agents. In addition, several new cytotoxic agents are being tested for efficacy in pancreatic cancer. Although these drugs may demonstrate clinically meaningful anti-tumor activity, none ofthem is expected to dramatically alter the natural history of this disease. However, with the identification of the molecular events involved in pancreatic carcinogenesis, invasion, and metastasis, new agents with specific molecular targets are being developed and tested in the clinic. These targets include matrix metalloproteinases, the K-ras oncoprotein, the tumor suppressor p53, HER2, epidermal growth factor receptor, and vascular endothelialgrowth factor. These molecular approaches provide an exciting opportunity to improve outcomes for patients with pancreatic cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 11:24:13